ONO-2020

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

1

Dayvigo

Eisai

Approved

12

Leqembi

Eisai

Approved

13

Avandia

Jazz Pharmaceuticals

Approved

—4

Rifadin

Sanofi

Approved

—5

Estrace

Novo Nordisk

Approved

—6

Aleve

Jazz Pharmaceuticals

Approved

—7

Avelox

Bayer

Approved

—8

Epidiolex

Jazz Pharmaceuticals

Approved

—9

Victoza

Novo Nordisk

Approved

—10

Cialis

Eli Lilly

Approved

—Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Agitation1 trial

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

Recruiting·Ono Pharmaceutical Co. Ltd·Phase 2·NCT06803823·90 enrolled

Phase 11 trial

A Phase 1 Study of ONO-2020 in Healthy Participants

Completed·Ono Pharmaceutical Co. Ltd·Phase 1·NCT05507515·132 enrolled

Alzheimer disease1 trial

A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease

Active, not recruiting·Ono Pharmaceutical Co. Ltd·Phase 2·NCT06881836·260 enrolled

Details

Drug Info

Related News